Phenobarbital and Risperidone interaction

Phenobarbital and Risperidone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Phenobarbital (SEZABY) label · effective 2025-12-23

Major

CNS depressants: Closely monitor for sedation and respiratory depression.

Drug interactionsby drug classView label on DailyMed
Major

Drugs that Prolong the QT Interval : Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

CNS Depressants Closely monitor for signs of sedation and respiratory depression with concomitant use of SEZABY with other CNS depressants, including opioids [see Warnings and Precautions (5.1)] .

Drug interactionsby drug classView label on DailyMed
Moderate

QT Prolongation SEZABY may prolong the QT interval [see Clinical Pharmacology (12.2)] .

Warnings and precautionsby drug classView label on DailyMed
Moderate

Drugs that Prolong QT Interval SEZABY may prolong the QT interval [see Warnings and Precautions (5.10) and Clinical Pharmacology (12.2)] .

Drug interactionsby drug classView label on DailyMed

From the Risperidone (RISPERDAL CONSTA) label · effective 2025-11-05

Moderate

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone.

Drug interactionsby drug classView label on DailyMed
Moderate

Carbamazepine and Other CYP 3A4 Enzyme Inducers Carbamazepine co-administration with oral RISPERDAL decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.

Drug interactionsby drug classView label on DailyMed
Moderate

Co-administration of other known CYP 3A4 enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of RISPERDAL CONSTA treatment.

Drug interactionsby drug classView label on DailyMed
Moderate

At the initiation of therapy with carbamazepine or other known hepatic enzyme inducers, patients should be closely monitored during the first 4–8 weeks, since the dose of RISPERDAL CONSTA may need to be adjusted.

Drug interactionsby drug classView label on DailyMed
Moderate

On discontinuation of carbamazepine or other CYP 3A4 hepatic enzyme inducers, the dosage of RISPERDAL CONSTA should be re-evaluated and, if necessary, decreased.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.